DrugDev's new 17,000 SF office in Boston's Innovation District
By situating our team in the heart of Boston’s renowned development community, we will continue to build solutions that make a real difference in how clinical trials are run.
Boston MA (PRWEB) November 10, 2016
DrugDev continues to transform how clinical trials are run with innovative technology. In order to meet increased demand and cultivate a gold standard collaborative environment for developers, the company has relocated its Newton, MA operations to 17,000 SF of modern space at 25 Thomson Place in the heart of Boston’s Innovation District.
Historically, drug development has lagged far behind other industries and consumer markets in terms of technology adoption. In recent years this has begun to change as true technology companies such as DrugDev have combined clinical operations best practices with proven cloud-based solutions that deliver a beautiful experience to users. Today, most of the world’s top pharma companies use key solutions on DrugDev’s clinical operations suite to significantly reduce the complexity, time and cost of running clinical trials – enabling them to improve the speed the delivery of new treatments to patients.
Moving to Boston’s Innovation District provides the company with direct access to the area’s inherent and unique intersection of cutting-edge technology developers and pharmaceutical expertise.
“We’re drawing developers from one of the world’s best and deepest pools of technology and pharmaceutical talent to build our solutions, because that’s what our customers deserve,” said Brian Fisher, Business Unit Chief Operating Officer. “Great people want to work here, and now the convenient location and collaborative environment of our Boston office makes it easier for them to join our team. Employees believe in what we are doing – helping the world run better trials to get more drugs to patients – and our office is modeled after the most modern open environments to inspire creativity and collaboration.”
Over the past 18 months the Boston operation has doubled its office space twice over, and tripled its development team as demand for DrugDev technology and services has soared.
“Despite all of the world’s technological advances, developing a new drug today costs 10 times as much as it did 30 years ago – can you believe that?” asked Ibraheem “Ibs” Mahmood, DrugDev President and CEO. “When you consider how much research and how many people are involved – not to mention time and money – with bringing a new drug to market, pharmaceutical companies and CROs cannot afford to accept the old way of doing things. Nor is it sustainable for internal study teams and clinical sites around the world to use dozens of disparate systems with clunky interfaces that don’t talk to each other, which leads to frustration and drags out timelines even further. Thankfully, times are changing – and by situating our team right in the heart of Boston’s renowned development community, we will continue to build solutions that make a real difference in how clinical trials are run.”
DrugDev is headquartered in King of Prussia, PA, with European operations centered in London. DrugDev’s Boston office makes a natural addition to the Innovation District because of its expert developer talent, life sciences focus and progressive spirit.
To become part of a world-class development or support team disrupting clinical research, or if you know someone who would excel in the environment, view the list of open job postings or contact Director of Talent, Larry McSheffery at larry.mcsheffery(at)drugdev(dot)com or +1 617-952-4071, x120.
About DrugDev
DrugDev’s unified clinical suite enables sponsors, CROs and sites to do more trials through industry-wide collaboration, standardization and a beautiful technology experience. Featuring solutions for global site payments, site identification and activation, workflow optimization, learning management, and site and patient engagement, DrugDev helps companies transform the quality and efficiency of clinical trials from startup through closeout. The company also powers the revolutionary TransCelerate Investigator Registry and Investigator Databank collaborations with the universal identifier known as the DrugDev Golden
Number. Learn more at drugdev.com